Drug-induced interstitial lung disorders, unspecified
ICD-10 J70.4 is a billable code used to indicate a diagnosis of drug-induced interstitial lung disorders, unspecified.
Drug-induced interstitial lung disorders, unspecified (J70.4) refers to a group of lung diseases characterized by inflammation and scarring of the lung tissue due to exposure to certain medications. Clinically, patients may present with symptoms such as dyspnea (shortness of breath), cough, and fatigue, which can develop gradually or acutely depending on the drug involved. The anatomy primarily affected includes the alveoli and interstitial spaces of the lungs, leading to impaired gas exchange. Disease progression can vary; some patients may experience a rapid decline in lung function, while others may have a more chronic course. Diagnostic considerations include a thorough patient history to identify potential drug exposures, imaging studies like chest X-rays or CT scans to assess lung involvement, and pulmonary function tests to evaluate the extent of lung impairment. A multidisciplinary approach may be necessary for accurate diagnosis and management, often involving pulmonologists and pharmacologists.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
J70.4 encompasses various interstitial lung disorders caused by drugs, including but not limited to, those induced by antibiotics, anti-inflammatory medications, and chemotherapeutic agents. The diagnosis is often made when no other specific cause can be identified, and the patient's history reveals recent drug exposure.
J70.4 should be used when the specific drug causing the interstitial lung disorder is unknown or unspecified. If the drug is known, a more specific code should be selected to accurately reflect the diagnosis.
Documentation should include a comprehensive drug history, clinical symptoms, results from imaging studies, and pulmonary function tests. It is crucial to document any changes in symptoms following the discontinuation of the suspected drug.
